<DOC>
	<DOCNO>NCT01970462</DOCNO>
	<brief_summary>This randomize controlled trial determine safety efficacy Sitagliptin patient stress hyperglycemia mild diabetes follow cardiac surgery . Patients receive Sitagliptin placebo . Sitagliptin may particular use patient population due effect hepatic glucose production ( major feature SH ) , safety ( lack contra-indications heart failure renal failure hypoglycemia ) , tolerability . The secondary objective study determine whether management patient persistent insulin requirement follow cardiac surgery differs among patient stress hyperglycemia mild diabetes .</brief_summary>
	<brief_title>Use Sitagliptin Stress Hyperglycemia Mild Diabetes Following Cardiac Surgery</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Hyperglycemia</mesh_term>
	<mesh_term>Polystyrene sulfonic acid</mesh_term>
	<mesh_term>Sitagliptin Phosphate</mesh_term>
	<criteria>Either following : Mild Diabetes Mellitus Stress Hyperglycemia AND : Cardiac Surgery Insulin Requirement 830 unit subcutaneous postop day 3 later pressor , enteral feeding , extubated OR glucose &gt; 150 mg/dL least twice 24 hour period ( &gt; 4 hour apart ) otherwise require basal insulin use pressor , mechanical ventilation , enteral parenteral feeding within previous 12 hour glucocorticoids dos exceed equivalent Prednisone 10 mg/day within previous 48 hour leave ventricular assist device percutaneous laparoscopic surgery end stage renal disease end stage liver disease history pancreatitis type 1 diabetes pregnancy unable give consent english phone prisoner less 18 year age</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>